Center for Medicinal Cannabis Research (CMCR @ UCSD)

📣 New Research: Nabiximols 🌿
Real-world data from Scotland show oral nabiximols (1:1 THC:CBD) associated with meaningful reductions in treatment-resistant spasticity in MS and other groups.

🔗 https://f.mtr.cool/dpuxjysipe
#CannabisResearch

📢 1 week until the deadline!
We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT
🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/zhhsjoouun

#CMCRGrantsProgram

📣 New Review: Cannabis & Heart Risk ❤️ Narrative review finds inconsistent evidence on cannabis and MI/stroke/MACE, but a more consistent signal for atrial arrhythmias; studies limited by misclassification and confounding.

🔗 https://f.mtr.cool/tttxvkyour
#CannabisResearch

📆 Save the Date: Oct 1–2! The 2026 CMCR Symposium: Cannabis & Sport explores the science of performance & recovery. Virtual & Free! 🧠🏃‍♂️
Register: https://f.mtr.cool/ihhescinkl #CMCRSymposium

Elderly couple enjoys smoking cannabis together in a cozy living room.

📣 New Study 🌙 Older adults (n=3,379; ≥50): 21% used cannabis in past year. Top motives: relaxation (81%) and sleep (68%). Among ≥monthly users, 44% hadn’t discussed use with a clinician. 🔗 https://f.mtr.cool/rgjprflghl #CannabisResearch

📣 New Review 🌱 Comprehensive review shows CBG & CBGA have promising anti-inflammatory, neuroprotective, and analgesic pharmacology, but human clinical evidence remains limited.

🔗 https://f.mtr.cool/azkwrhqwtv
#CannabisResearch

📣 New Study 🌙
RCT in people with MS found oral nabiximols (1:1 THC:CBD) significantly improved sleep (PSQI) vs placebo. Short follow-up, but promising clinical signal.

🔗 https://f.mtr.cool/egkcsehvxz
#CannabisResearch

🌿 New systematic review (64 studies, 43k+ pts): medicinal cannabis linked to small–moderate improvements in health-related quality of life, though many studies lacked clear HRQL definitions. Better reporting needed.

🔗 https://f.mtr.cool/gojjxoudca
#CannabisResearch

📢 CMCR 2026 RFA Released! We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT
🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/xuuktgxstp

#CMCRGrantsProgram

📣 New Research 🧠
Moderate lifetime cannabis use was associated with larger brain volumes and better cognition in adults 40–70 (UK Biobank). Cross-sectional MRI + cognitive testing (n>25k). Age-dependent effects may matter.

🔗 https://f.mtr.cool/qhzkcubpnz
#CannabisResearch

📣 Participate in a study examining the impact of using high-THC cannabis dispensary products on driving ability
📣 Also enrolling those with minimal to no experience with cannabis 
Compensation: Up to $360
Contact:
(619) 543-5000
hnrpstudies@health.ucsd.edu
https://f.mtr.cool/usatmmuhkx

📢 Acute CBD, anxiety, and perceived exertion🔬
Acute CBD (300 mg) increased calmness and reduced perceived effort during a 2-mile run, without improving or impairing performance in recreational runners. 🏃‍♀️🌿
🔗 https://f.mtr.cool/vzadvhlddx
#CannabisResearch

📢 CMCR 2026 RFA Released! We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT
🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/mwyunvktsz

#CMCRGrantsProgram

🎙️ New Podcast | Cannabis & Driving Laws
Dr. Tom Marcotte, PhD, and Robert Fitzgerald, PhD, discuss new Clinical Chemistry research showing that “per se” blood THC limits can label regular users as impaired—even when driving performance is unchanged.
https://f.mtr.cool/jbbtcgisgv
#CannabisResearch

📣 Participate in a study examining the impact of using high-THC cannabis dispensary products on driving ability 

Call or e-mail a representative!
(619) 543-5000
hnrpstudies@health.ucsd.edu
For more info: https://f.mtr.cool/kjgambqfur

#CannabisResearch #DrivingSafety #CannabisImpairedDriving

📢 New Research | Cannabis & Driving
Dr. Tom Marcotte, PhD, and CMCR colleagues are featured in a UCSD Today article on the MADDI study, using a mobile lab to assess driving, attention, and memory before and after high-THC vaping or dabbing in real-world settings.
#CannabisResearch

📢 New Phase 3 trial: Cannabis extract and low back pain relief🔬
A full-spectrum cannabis extract significantly reduced pain and improved sleep & function in adults with chronic low back pain vs placebo. 🌿💊
🔗 https://f.mtr.cool/kgjqivgxzg
#CannabisResearch

🔬📢 New randomized, double-blind crossover pilot study
Acute CBD (150 mg) had no effect on VO2peak or time to exhaustion in recreationally active adults, suggesting no aerobic performance benefit or harm. 🏃‍♂️🌿
🔗 https://f.mtr.cool/uqvieqrggh
#CannabisResearch

📢 CMCR 2026 RFA Released! We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT 🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/oyqewnlrih

#CMCRGrantsProgram

🔬📢 New alcohol–cannabis laboratory study
Cannabis use before drinking was linked to fewer drinks consumed and reduced alcohol craving in some heavy-drinking adults. Suggests substitution may occur for certain individuals. 🍺➡️🌿
🔗 https://f.mtr.cool/bneatqihwo
#CannabisResearch

🌿 Did you miss the January CMCR Investigators’ Meeting? 🎙️ No worries—you can now watch Dr. Daniele Piomelli's presentation on Cannabinoids for the Treatment of Pain: The Case of Sickle-Cell Anemia🔬✨
🎥 Watch here → https://f.mtr.cool/tpkbdyelwa
#CannabisResearch #CMCR

UCSD study on high-THC cannabis and driving ability.
Compensation up to $360.
https://f.mtr.cool/lxietakpwu
#CannabisResearch

🔬📢 New longitudinal observational study
Adults initiating medical cannabis reported sustained improvements in subjective sleep quality over 12 months. Observational and self-reported data—controlled trials needed. 🔗 https://f.mtr.cool/kculiwitxo #CannabisResearch

📢 CMCR 2026 RFA Released! We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT 🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/ewtmuxhpvk

#CMCRGrantsProgram

Frontiers | Exploring the neuroprotective effects and underlying mechanisms of medical cannabinoids in ischemic stroke: a systematic meta-analysis with bibliometric mapping of cerebral ischemia research BackgroundIschemic stroke is an acute neurological disorder with limited treatment options. Medical cannabinoids (MCs), primary bioactive compounds extracted...

🔬📢 New systematic review and meta-analysis of animal studies
Cannabinoids improved outcomes in animal models of ischemic stroke, reducing infarct size, inflammation, and oxidative stress. Findings are preclinical and require human trials.
🔗 https://f.mtr.cool/cxbrpeoeyi
#CannabisResearch

UCSD study on high-THC cannabis and driving ability.
Compensation up to $360.
https://f.mtr.cool/lxietakpwu
#CannabisResearch

📢 New research:
A randomized study of 23 fibromyalgia patients found THC reduced pain and improved offset analgesia. Baseline OA predicted pain relief, suggesting potential for personalized cannabinoid treatment.
https://f.mtr.cool/kywbtjzdoo
#CannabisResearch

🌿 Did you miss the January CMCR Investigators’ Meeting? 🎙️ No worries—you can now watch Dr. Daniele Piomelli's presentation on Cannabinoids for the Treatment of Pain: The Case of Sickle-Cell Anemia🔬✨
🎥 Watch here → https://f.mtr.cool/evbkfqprxy
#CannabisResearch #CMCR

📢 CMCR 2026 RFA Released! We are actively funding studies on cannabis efficacy & adverse effects for medical/psychiatric disorders.

🗓️ LOI Due: Mar 6, 5pm PT 🗓️ App Due: Apr 24, 5pm PT

More info here: https://f.mtr.cool/fdquueffxj

#CMCRGrantsProgram

📆 Save the Date: Oct 1–2! The 2026 CMCR Symposium: Cannabis & Sport explores the science of performance & recovery. Virtual & Free! 🧠🏃‍♂️
Register: https://f.mtr.cool/urduwjecvz #CMCRSymposium